Parexel announced the opening of its new European Coordination Hub and Distribution Center in Berlin-Sch?nefeld.
Parexel announced the opening of its new European Coordination Hub and Distribution Center in Berlin-Schönefeld, Germany. Its capabilities include synchronized coordination of clinical trial supplies, ancillary supplies and central laboratory services and features more than 65,000 cubic meters of storage space. It offers lab-kit assembly and provides storage and distribution of ancillary materials.
The new European Coordination Hub and Distribution Center will be licensed to store Investigational Medicinal Products (IMPs) and Non-Investigational Medicinal Products (N-IMPs). It will also offer secondary packaging, re-labeling, and compliance with Good Distribution Practice (GDP) of medical devices and ambient, refrigerated and frozen medicinal products, including controlled substances. On-site Qualified Person (QP), Quality Control (QC) and production personnel will manage regulatory-compliance requirements. They will also streamline product import, receipt, storage, packaging and labeling, release, shipment, return and destruction timelines.
PAREXEL also is opening new full-service clinical trial supply depots in Buenos Aires, Argentina, and São Paulo, Brazil. The facilities are part of PAREXEL’s growing global system of more than 50 owned or in-network depots and three regional distribution centers.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.